With Servier picking up the tab, basically XOMA has a free shot on goal in both the ACS and diabetes indications. If either one of them pans out, the company has the ability to reacquire the US/Japan rights. Nice deal.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.